1. Scrip
  2. >>Business

Will Yabao Help Lupin’s Attempts To Scale The Great Wall?

 
• By Vibha Ravi and Brian Yang

With the Yabao partnership, Lupin builds on a toehold gained through the Foncoo tie-up as it attempts to scale the market behind the Great Wall of China. Scrip takes a look at possible approaches and potential of the partnership

Hands painted with India and China flags going for a handshake
The Lupin-Yabao Alliance Creates Opportunities For Both Companies • Source: Shutterstock

When Lupin Limited tied up with Guangdong-based Shenzhen Foncoo Pharmaceutical Co. Ltd late this January, it had spelled out a plan to add more partners to broad base its presence in the Chinese market. In just three and a half months since, the company has struck a marketing deal with Yabao Pharmaceutical Group's Yabao Pharmaceutical&Co. Inc. (Also see "Lupin’s Foncoo Partnership Beginning Of China Challenge To AZ, Cipla?" - Scrip, 24 January, 2022.)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.